Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

TP Therapeutics completes $80mm mezzanine round

Executive Summary

TP Therapeutics Inc. (precision oncology) raised $80mm from a mezzanine round co-led by venBio Partners and Foresite Capital. New investors HBM Healthcare Investments and Nextech Invest were joined by returning backers Cormorant Asset Management, Lilly Asia Ventures, Orbimed Advisors, and SR One. The company will use some of the funds to advance lead candidate repotrectinib (a ROS1/TRKs/ALK inhibitor) into a Phase II trial for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register